RTS,S malaria vaccine candidate

View RTS,S timeline

Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children

Results from ongoing Phase III clinical trial announced

Further results from the Phase III efficacy trial of the RTS,S malaria vaccine candidate were presented on Tuesday, 8 October, at the 6th Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference in Durban, South Africa. These latest results demonstrated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases in young children (aged 5-17 months at first vaccination) and to reduce by around a quarter the malaria cases in infants (aged 6-12 weeks at first vaccination).

RTS,S timeline

Navigate through the RTS,S timeline below to find out more about the development of RTS,S. Click on a year or year range along the bottom to see that section of the timeline.